Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R4 R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

Abstract: The present invention encompasses compounds of general Formula (1) wherein R1 to R4 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R3 and X are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R4, m and n are defined as in the specification, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

Abstract: Compounds of a certain formula (I), in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors.

Abstract: Compounds of a certain formula (I) in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors.

Abstract: In a method for automatically evaluating data from at least one clinical study, data may be assessed at a study management system based on at least one management criteria. At least one measured variable may be determined based on the assessed data, and at least one action correlated to at least one facility may be initiated based on the at least one measured variable. The at least one management criteria may be associated with the at least one clinical study.

Abstract: In a method for determining a parameter in an automatic study and data management system, data is gathered in a knowledge database, and a parameter is determined based the data gathered in the knowledge database. The data is correlated to at least one of a configuration and implementation of a previous clinical study. The parameter is usable for configuring a future clinical study.

Abstract: Compounds of a certain formula (I) in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors.

Abstract: In a method and a system for supporting the evaluation of a picture of a patient's eye the picture is displayed on a screen. An image-processing algorithm from a number of image processing algorithms is selected due to a preliminary diagnosis selected from a number of diagnoses which are related to diabetes. Each image-processing algorithm of the number of image processing algorithms is associated with a diagnosis of the number of diagnoses and is designed to search for a pattern which is specific to the respective diagnosis. The selected image-processing algorithm then is applied to the picture and a pattern which is detected by the selected image-processing algorithm is marked on the screen in the picture.

Abstract: A method is for verifying the feasibility of a medical study using acceptance criteria for patients. The method includes defining target criteria for the study. Based on the acceptance criteria, a patient collective including potential patients is selected from a database containing patient data of patients. The patient data of the patient collective are evaluated based on the target criteria. Finally, a measure for the feasibility of the study is established.

Abstract: A method is for evaluating the quality of electronically stored, particularly medical, knowledge data. The knowledge data are stored in a database; quality data correlated with the knowledge data are stored in the database, and; when a user accesses the knowledge data, the quality data are automatically provided to the user.

Abstract: A method is disclosed for carrying out quality control of medical data records collected from different but comparable patient collectives within the bounds of a medical plan. In the method, for each data record, a quality control parameter assigned thereto is determined in the same manner. Further, the quality control parameters are evaluated using comparison criteria.

Abstract: A method is disclosed for verifying whether an implementation rule assigned to a medical procedure has been observed. The method includes: data correlated with the procedure is automatically entered and stored in a data processing device; test criteria for the data, which are correlated with the implementation rule, are stored in a test system; the procedure is implemented; the test system reads out the data from the data processing device; and the test system evaluates the data based on the test criteria and determines to what degree the implementation rule has been observed.

Abstract: During a method for selecting a potential participant for a medical study on the basis of a selection criterion, patient data assigned to a patient are electronically stored. A secondary criterion is assigned to the selection criterion. The patient data are electronically evaluated on the basis of the secondary criterion. Based on this electronic evaluation, a measure for fulfilling the selection criterion is determined for the patient associated with the patient data. The patient is selected as a potential participant on the basis of this measure.

Abstract: A method is disclosed for performing a clinical study on a patient. The study-related or patient-related data is stored in a memory during the study. The memory is readable by a physician who is foreign to the study and is associated with the patient. An information system for a clinical study on a patient encompasses a memory for study-related or patient-related data, which is allocated to the patient, a data input device for storing data in the memory, and a data reading device for reading out the data from the memory. The data reading device is accessible to a physician who is foreign to the study and is associated with the patient.

Abstract: A method is disclosed for conducting a clinical study according to which an event occurs during the study that requires a collaboration of individuals responsible for the study. The method includes transmitting the event to a collaboration system. The collaboration system determines, based on parameters assigned to the event, a group of individuals responsible for the study required for the collaboration. The collaboration system provides a communications platform for the group. The group carries out the collaboration while using the communications platform. Finally, the collaboration system verifies the collaboration on the basis of predetermined verification criteria.

Abstract: A device for additive-free, catalytically induced oxidation of solid carbon particles and decomposition of chemical compounds, comprising a converter chamber with compartments, in which porous structure catalyst carrier matrix profiles are mounted, so that a space between the internal diameter of catalyst profiles is connected to an inlet connection of the converter chamber, and a space around the external diameter of the catalyst profiles is connected to an outlet connection into the catalyst chamber. The profiles are mounted so that gas particles reach outlets only by passing through porous profiles. Advantageously, a third opening through which liquid, gaseous media, e.g., NO2, O3 or H2O or auxiliary means maybe in front of the porous structures. The porous structures are made of catalytically active material with catalytic action at temperatures below 400° C., preferably below 350° C. and especially below 300° C. The low-temperature below 250° C. by H2O is preferred.